REFERENCES
Aklillu, E., Zumla, A., Habtewold, A., Amogne, W., Makonnen, E., Yimer,
G., et al. (2020). Early or deferred initiation of efavirenz during
rifampicin-based TB therapy has no significant effect on CYP3A induction
in TB-HIV infected patients. Br. J. Pharmacol. n/a :
Alexander, S.P.H., Christopoulos, A., Davenport, A.P., Kelly, E.,
Mathie, A., Peters, J.A., et al. (2019). THE CONCISE GUIDE TO
PHARMACOLOGY 2019/20: G protein-coupled receptors. Br. J. Pharmacol.176 : S21–S141.
Alonso, A., Marsal, S., and Julià, A. (2015). Analytical Methods in
Untargeted Metabolomics: State of the Art in 2015. Front. Bioeng.
Biotechnol. 3 :.
Beger, R.D., Dunn, W., Schmidt, M.A., Gross, S.S., Kirwan, J.A.,
Cascante, M., et al. (2016). Metabolomics enables precision medicine: ‘A
White Paper, Community Perspective’. Metabolomics Off. J. Metabolomic
Soc. 12 : 149.
Blaženović, I., Kind, T., Ji, J., and Fiehn, O. (2018). Software Tools
and Approaches for Compound Identification of LC-MS/MS Data in
Metabolomics. Metabolites 8 : 31.
Crews, K.R., Gaedigk, A., Dunnenberger, H.M., Leeder, J.S., Klein, T.E.,
Caudle, K.E., et al. (2014). Clinical Pharmacogenetics Implementation
Consortium guidelines for cytochrome P450 2D6 genotype and codeine
therapy: 2014 update. Clin. Pharmacol. Ther. 95 : 376–382.
Curtis, M.J., Alexander, S., Cirino, G., Docherty, J.R., George, C.H.,
Giembycz, M.A., et al. (2018). Experimental design and analysis and
their reporting II: updated and simplified guidance for authors and peer
reviewers. Br. J. Pharmacol. 175 : 987–993.
Daali, Y., Cherkaoui, S., Doffey-Lazeyras, F., Dayer, P., and Desmeules,
J.A. (2008). Development and validation of a chemical hydrolysis method
for dextromethorphan and dextrophan determination in urine samples:
Application to the assessment of CYP2D6 activity in fibromyalgia
patients. J. Chromatogr. B 861 : 56–63.
Dias, D.A., Jones, O.A.H., Beale, D.J., Boughton, B.A., Benheim, D.,
Kouremenos, K.A., et al. (2016). Current and Future Perspectives on the
Structural Identification of Small Molecules in Biological Systems.
Metabolites 6 : 46.
Dührkop, K., Fleischauer, M., Ludwig, M., Aksenov, A.A., Melnik, A.V.,
Meusel, M., et al. (2019). SIRIUS 4: a rapid tool for turning tandem
mass spectra into metabolite structure information. Nat. Methods16 : 299–302.
Elens, L., Bouamar, R., Hesselink, D.A., Haufroid, V., Heiden, I.P. van
der, Gelder, T. van, et al. (2011). A new functional CYP3A4 intron 6
polymorphism significantly affects tacrolimus pharmacokinetics in kidney
transplant recipients. Clin. Chem. 57 : 1574–1583.
Farrell, E.K., and Merkler, D.J. (2008). Biosynthesis, degradation, and
pharmacological importance of the fatty acid amides. Drug Discov. Today13 : 558–568.
Forchelet, D., Béguin, S., Sajic, T., Bararpour, N., Pataky, Z., Frias,
M., et al. (2018). Separation of blood microsamples by exploiting
sedimentation at the microscale. Sci. Rep. 8 : 14101.
Gaedigk, A. (2013). Complexities of CYP2D6 gene analysis and
interpretation. Int. Rev. Psychiatry Abingdon Engl. 25 : 534–553.
Gaedigk, A., Dinh, J.C., Jeong, H., Prasad, B., and Leeder, J.S. (2018).
Ten Years’ Experience with the CYP2D6 Activity Score: A Perspective on
Future Investigations to Improve Clinical Predictions for Precision
Therapeutics. J. Pers. Med. 8 : 15.
Gaedigk, A., Simon, S.D., Pearce, R.E., Bradford, L.D., Kennedy, M.J.,
and Leeder, J.S. (2008). The CYP2D6 activity score: translating genotype
information into a qualitative measure of phenotype. Clin. Pharmacol.
Ther. 83 : 234–242.
Harding, S.D., Sharman, J.L., Faccenda, E., Southan, C., Pawson, A.J.,
Ireland, S., et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in
2018: updates and expansion to encompass the new guide to
IMMUNOPHARMACOLOGY. Nucleic Acids Res. 46 : D1091–D1106.
Hicks, J., Bishop, J., Sangkuhl, K., Müller, D., Ji, Y., Leckband, S.,
et al. (2015). Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of
Selective Serotonin Reuptake Inhibitors. Clin. Pharmacol. Ther.98 : 127–134.
Ingelman-Sundberg, M. (2005). Genetic polymorphisms of cytochrome P450
2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional
diversity. Pharmacogenomics J. 5 : 6–13.
Ivanisevic, J., and Thomas, A. (2018). Metabolomics as a Tool to
Understand Pathophysiological Processes. Methods Mol. Biol. Clifton NJ1730 : 3–28.
Jensen, B.C., Parry, T.L., Huang, W., Beak, J.Y., Ilaiwy, A., Bain,
J.R., et al. (2017). Effects of the kinase inhibitor sorafenib on heart,
muscle, liver and plasma metabolism in vivo using non-targeted
metabolomics analysis. Br. J. Pharmacol. 174 : 4797–4811.
Kaddurah-Daouk, R., Weinshilboum, R.M., and Pharmacometabolomics
Research Network (2014). Pharmacometabolomics: implications for clinical
pharmacology and systems pharmacology. Clin. Pharmacol. Ther. 95 :
154–167.
Karnes, J.H., Rettie, A.E., Somogyi, A.A., Huddart, R., Fohner, A.E.,
Formea, C.M., et al. (2020). Clinical Pharmacogenetics Implementation
Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin
Dosing: 2020 Update. Clin. Pharmacol. Ther. n/a :
Kim, B., Lee, J., Shin, K.-H., Lee, S., Yu, K.-S., Jang, I.-J., et al.
(2018). Identification of ω- or (ω-1)-Hydroxylated Medium-Chain
Acylcarnitines as Novel Urinary Biomarkers for CYP3A Activity. Clin.
Pharmacol. Ther. 103 : 879–887.
Kohler, I., Hankemeier, T., Graaf, P.H. van der, Knibbe, C.A.J., and
Hasselt, J.G.C. van (2017). Integrating clinical metabolomics-based
biomarker discovery and clinical pharmacology to enable precision
medicine. Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci. 109S :
S15–S21.
Kowalczuk, L., Matet, A., Dor, M., Bararpour, N., Daruich, A., Dirani,
A., et al. (2018). Proteome and Metabolome of Subretinal Fluid in
Central Serous Chorioretinopathy and Rhegmatogenous Retinal Detachment:
A Pilot Case Study. Transl. Vis. Sci. Technol. 7 : 3.
Langaee, T., Hamadeh, I., Chapman, A.B., Gums, J.G., and Johnson, J.A.
(2015). A Novel Simple Method for Determining CYP2D6 Gene Copy Number
and Identifying Allele(s) with Duplication/Multiplication. PLOS ONE10 : e0113808.
Lee, C. (1995). Urinary 6βP-hydroxycortisol in humans: Analysis,
biological variations, and reference ranges. Clin. Biochem. 28 :
49–54.
Lima, J.J., Thomas, C.D., Barbarino, J., Desta, Z., Van Driest, S.L., El
Rouby, N., et al. (2020). Clinical Pharmacogenetics Implementation
Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor
Dosing. Clin. Pharmacol. Ther.
Magliocco, G., and Daali, Y. (2020). Modern approaches for the
phenotyping of cytochrome P450 enzymes in children. Expert Rev. Clin.
Pharmacol. 0 : 1–4.
Magliocco, G., Thomas, A., Desmeules, J., and Daali, Y. (2019).
Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge
and Methodological Approaches. Clin. Pharmacokinet. 58 :
1373–1391.
Mao, J., Martin, I., McLeod, J., Nolan, G., Horn, R. van, Vourvahis, M.,
et al. (2017). Perspective: 4β-hydroxycholesterol as an emerging
endogenous biomarker of hepatic CYP3A. Drug Metab. Rev. 49 :
18–34.
Nofziger, C., Turner, A.J., Sangkuhl, K., Whirl-Carrillo, M., Agúndez,
J.A.G., Black, J.L., et al. (2020). PharmVar GeneFocus: CYP2D6. Clin.
Pharmacol. Ther. 107 : 154–170.
Pang, H., Jia, W., and Hu, Z. (2019). Emerging Applications of
Metabolomics in Clinical Pharmacology. Clin. Pharmacol. Ther.106 : 544–556.
Peñas-LLedó, E.M., and LLerena, A. (2014). CYP2D6 variation, behaviour
and psychopathology: implications for pharmacogenomics-guided clinical
trials. Br. J. Clin. Pharmacol. 77 : 673–683.
Samer, C.F., Lorenzini, K.I., Rollason, V., Daali, Y., and Desmeules,
J.A. (2013). Applications of CYP450 testing in the clinical setting.
Mol. Diagn. Ther. 17 : 165–184.
Schmidt, L., Müller, J., and Göen, T. (2013). Simultaneous monitoring of
seven phenolic metabolites of endocrine disrupting compounds (EDC) in
human urine using gas chromatography with tandem mass spectrometry.
Anal. Bioanal. Chem. 405 : 2019–2029.
Schrimpe-Rutledge, A.C., Codreanu, S.G., Sherrod, S.D., and McLean, J.A.
(2016). Untargeted Metabolomics Strategies-Challenges and Emerging
Directions. J. Am. Soc. Mass Spectrom. 27 : 1897–1905.
Shah, R.R., Gaedigk, A., LLerena, A., Eichelbaum, M., Stingl, J., and
Smith, R.L. (2016). CYP450 genotype and pharmacogenetic association
studies: a critical appraisal. Pharmacogenomics 17 : 259–275.
Snider, N.T., Sikora, M.J., Sridar, C., Feuerstein, T.J., Rae, J.M., and
Hollenberg, P.F. (2008). The endocannabinoid anandamide is a substrate
for the human polymorphic cytochrome P450 2D6. J. Pharmacol. Exp. Ther.327 : 538–545.
Storelli, F., Desmeules, J., and Daali, Y. (2019). Genotype-sensitive
reversible and time-dependent CYP2D6 inhibition in human liver
microsomes. Basic Clin. Pharmacol. Toxicol. 124 : 170–180.
Tay-Sontheimer, J., Shireman, L.M., Beyer, R.P., Senn, T., Witten, D.,
Pearce, R.E., et al. (2014). Detection of an endogenous urinary
biomarker associated with CYP2D6 activity using global metabolomics.
Pharmacogenomics 15 : 1947–1962.
Thomas, A., Hopfgartner, G., Giroud, C., and Staub, C. (2009).
Quantitative and qualitative profiling of endocannabinoids in human
plasma using a triple quadrupole linear ion trap mass spectrometer with
liquid chromatography. Rapid Commun. Mass Spectrom. RCM 23 :
629–638.
Villaseñor, A., Ramamoorthy, A., Silva dos Santos, M., Lorenzo, M.P.,
Laje, G., Zarate, C., et al. (2014). A pilot study of plasma metabolomic
patterns from patients treated with ketamine for bipolar depression:
evidence for a response-related difference in mitochondrial networks.
Br. J. Pharmacol. 171 : 2230–2242.
Wake, D.T., Ilbawi, N., Dunnenberger, H.M., and Hulick, P.J. (2019).
Pharmacogenomics: Prescribing Precisely. Med. Clin. North Am.103 : 977–990.
Whiley, L., Chekmeneva, E., Berry, D.J., Jiménez, B., Yuen, A.H.Y.,
Salam, A., et al. (2019). Systematic Isolation and Structure Elucidation
of Urinary Metabolites Optimized for the Analytical-Scale Molecular
Profiling Laboratory. Anal. Chem. 91 : 8873–8882.
Xia, J., and Wishart, D.S. (2011). Web-based inference of biological
patterns, functions and pathways from metabolomic data using
MetaboAnalyst. Nat. Protoc. 6 : 743–760.
Yeung, P.K. (2018). Metabolomics and Biomarkers for Drug Discovery.
Metabolites 8 : 11.
Zhang, H., Basit, A., Wolford, C., Chen, K.-F., Gaedigk, A., Lin, Y.S.,
et al. (2020). Normalized Testosterone Glucuronide as a Potential
Urinary Biomarker for Highly Variable UGT2B17 in Children 7–18 Years.
Clin. Pharmacol. Ther. 107 : 1149–1158.